Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Next Previous
X
Search
Trial Profile

A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NRTX-1001 (Primary)
  • Indications Partial epilepsies; Seizures; Temporal-lobe-epilepsy
  • Focus Adverse reactions; First in man
  • Sponsors Neurona Therapeutics

    • Most Recent Events

    • 10 Sep 2024 According to a Neurona Therapeutics media release, company announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $3.8M grant to support the development of a next generation neural cell therapy candidate NRTX-1001 in view of the highly encouraging initial data from its ongoing Phase 1/2 clinical trial in adults with drug-resistant epilepsy.
    • 18 Jun 2024 According to a Neurona Therapeutics media release, company announced that the U.S Food and Drug Administration (FDA) has granted the company's lead product candidate, NRTX-1001,the RMAT expedited program designation for drug-resistant mesial temporal lobe epilepsy (MTLE).
    • 15 Apr 2024 According to a Neurona Therapeutics media release, enrollment is currently underway at epilepsy centers across the United States.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top